Senseonics (NYSE:SENS) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

Senseonics Price Performance

NYSE SENS opened at $0.39 on Wednesday. The company has a debt-to-equity ratio of 1.79, a current ratio of 3.96 and a quick ratio of 3.70. Senseonics has a 1-year low of $0.37 and a 1-year high of $1.05. The stock has a market capitalization of $207.63 million, a price-to-earnings ratio of -2.79 and a beta of 0.82. The business’s fifty day moving average price is $0.43 and its 200-day moving average price is $0.52.

Senseonics (NYSE:SENS) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $4.76 million. Senseonics had a negative net margin of 346.38% and a negative return on equity of 202.32%. On average, equities analysts predict that Senseonics will post -0.12 earnings per share for the current year.

Institutional Trading of Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. RPO LLC purchased a new position in shares of Senseonics during the 4th quarter valued at about $37,000. State Board of Administration of Florida Retirement System purchased a new position in Senseonics during the first quarter valued at approximately $91,000. Virtu Financial LLC bought a new position in shares of Senseonics in the first quarter worth approximately $162,000. Price T Rowe Associates Inc. MD increased its stake in shares of Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the period. Hedge funds and other institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.